师资队伍

李永淑

发布者：生命科学学院发布时间：2024-06-18浏览次数：618

 


             李永淑   （1990年5月生）

博士       硕士研究生导师

E-mail：yongshuli000@163.com/1155127933@link.cuhk.edu.hk






个人简历

 ■教育经历

 2019-2022香港中文大学  医学院（威尔士亲王医院） 病理解剖与细胞学系 博士

 2011-2014华中师范大学 生命科学学院院     微生物学   硕士

 2007-2011湖北师范大学  生命科学学院院    生物技术    学士

 ■工作经历

 2014-2016中科院深圳先进技术研究院 医药所 基因与细胞治疗研究室      助理工程师

 2016-2018香港浸会大学            中医药学院                       研究访问学者

 2018-2019香港大学                医学院-生物医学院                 技术主任


研究领域

从事适配体筛选及应用方面的研究。通过cell-SELEX技术筛选到鼻咽癌靶向适配体Apt-2019和Apt-1194，利用Pulldown/质谱/WB/IF等技术发现适配体结合靶点/鼻咽癌治疗新靶点CNBP与MTDH蛋白，揭示其高表达机制。适配体在肿瘤中的特异性富集，适配体标记DNArobot可用于鼻咽癌手术荧光导航，适配体-5FU/gemcitabine偶联药物在临床前研究中显示出优异的靶向治疗效果，科研成果于香港科学园孵化ACE NanoMed公司。申请人以第一作者或通讯作者发表SCI论文7篇，总影响因子49.64，其中单篇最高引用达195次，参与发表其他SCI论文14篇，副主编专著一本。授权美国专利1项(No 63/267,737)，申请PCT专利一项(PCT/CN2023/075031)，荣获第49届日内瓦国际发明展银奖(2024)，荣获Open Science Excellent Author Program(Wiley)奖。


主要社会兼职

 2024-至今，湖北贝恩特生物科技有限公司 研发副总

承担的课程

分子生物学、生物化学、抗体制备技术及应用、生物技术制药与工艺、药物分析与检验等


主持的课题项目

■基于核酸适配体开发中药中5-羟甲基糠醛的检测方法研究（食用野生植物保育与利用

湖北省重点实验室开放课题基金，2024-2026）

■适配体与靶点结合机制研究（湖北师范大学人才引进项目，2024-2027）



代表性成果

 ■期刊论文

（1）Li Yongshu, Tam WW, Yu Y, Zhuo Z, Xue Z, Tsang C, Qiao X, Wang X, Wang W, Li Y, Tu Y, Gao Y. The application of Aptamer in biomarker discovery. Biomark Res. 2023 Jul 19;11(1):70. doi: 10.1186/s40364-023-00510-8. PMID: 37468977; PMCID: PMC10354955. (中科院2区 IF=11.1).

（2）Li Yongshu, Zhao J, Xue Z, Tsang C, Qiao X, Dong L, Li H, Yang Y, Yu B and Gao Y (2022), Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers. Front. Cell Dev. Biol. 10:1053984. doi: 10.3389/fcell.2022.1053984. (中科院2区 IF=5.5)  

（3）Li Yongshu, Huang B, Xue Z, Gao Y, Zhuo Z. Nucleic acid therapy in pediatric cancer. Pharmacol Res. 2022 Oct;184:106441. doi:10.1016/j.phrs.2022.106441. Epub2022 Sep 9. PMID: 36096420. (中科院1区 IF=9.3).

（4）Li Yongshu; Li Fangfei; Jiang Feng; Lv Quanxia; Zhang Rongjiang; Lu, Aiping; Zhang Ge. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway and Translational Blockade of Immune Checkpoints. International journal of molecular sciences 2016, 17. (中科院2区 IF=5.6).

（5）Ren J, Li Yongshu(Co-first Author), Hu S, Liu Y, Tsao SW, Lau D, Luo G, Tsang CM, Lam RHW. Nondestructive quantification of single-cell nuclear and cytoplasmic mechanical properties based on large whole-cell deformation. Lab Chip. 2020 Nov 10;20(22):4175-4185. doi: 10.1039/d0lc00725k. PMID: 33030494. (中科院1区 IF=6.1).

（6）Wang W, Li Yongshu*(Corresponding author), Lin K, Wang X, Tu Y, Zhuo Z*. Progress in building clinically relevant patient-derived tumor xenograft models for cancer research. Animal Model Exp Med. 2023 Oct;6(5):381-398. doi: 10.1002/ame2.12349. Epub 2023 Sep 7. PMID: 37679891; PMCID: PMC10614132. (IF=3.7)  

（7）Bi B, Qiu M, Liu P, Wang Q, Wen Y, Li Yongshu*(Corresponding author), Li B, Li Y, He Y*, Zhao J*. Protein post-translational modifications: A key factor in colorectal cancer resistance mechanisms. Biochim Biophys Acta Gene Regul Mech. 2023 Dec;1866(4):194977. doi: 10.1016/j.bbagrm.2023.194977. Epub 2023 Aug 23. PMID: 37625568. (中科院2区 IF=4.7).

（8）Xue Z, Lui VWY, Li Yongshu, Jia L, You C, Li X, Piao W, Yuan H, Khong PL, Lo KW, Cheung LWT, Lee VHF, Lee AWM, Tsao SW, Tsang CM. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2020 Nov 26;39(1):262. doi: 10.1186/s13046-020-01763-z. PMID: 33243298; PMCID: PMC7690146.

（9）Xue Z, Zeng J, Yin X, Li Yongshu, Meng B, Zhao Y, Fang X, Gong X, Dai X. Investigation on acquired palbociclib resistance by LC-MS based multi-omics analysis. Front Mol Biosci. 2023 Jan 19;10:1116398. doi: 10.3389/fmolb.2023.1116398. PMID: 36743215; PMCID: PMC9892630  

（10）Zhao J, Huang X, Liu P, Qiu M, Li B, Wen Y, Li Yongshu, Wang Q, Wu M, Chen Y, Pan Y. Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment. Adv Sci (Weinh). 2022 Oct;9(30):e2203031. doi: 10.1002/advs.202203031. Epub 2022 Sep 4. PMID: 36057999; PMCID: PMC9596851.

 (11) Ji D, Juhas M, Tsang CM, Kwok CK, Li Yongshu, Zhang Y. Discovery of G-quadruplex-forming sequences in SARS-CoV-2. Brief Bioinform. 2020 Jun 1:bbaa114. doi: 10.1093/bib/bbaa114. Epub ahead of print. PMID: 32484220; PMCID: PMC7314185.  

  1. Jifeng Ren, Jiyu Li, Yongshu Li, Peng Xiao, Yi Liu, Chi Man Tsang, Sai Wah Tsao, Denvid Lau, Kannie W. Y. Chan, and Raymond H. W. Lam. Elasticity-Modulated Microbeads for Classification of Floating Normal and Cancer Cells Using Confining Microchannels. ACS Biomaterials Science & Engineering 2019 5 (8), 3889-3898 DOI: 10.1021/acsbiomaterials.8b01273

  2. Wu X, Li F, Li Yongshu, Yu Y, Liang C, Zhang B, Zhao C, Lu A, Zhang G. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Med Sci Monit. 2020 Jun 23;26:e925583. doi: 10.12659/MSM.925583. PMID: 32574155; PMCID: PMC7331476.

  3. Wu Xiaoqiu,† Atik Badshah Shaikh,† Yu Yuanyuan,† Li Yongshu,† Ni Shuaijian,† Lu Aiping* and Zhang Ge *; Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. International journal of molecular sciences. 2017 Sep; 18(9): 18514.

  4. Li Fangfei, Lu Jun, Liu Jin, Liang Chao, Wang Maolin, Wang Luyao, Li Defang, Yao Houzong, Zhang Qiulong, Wen Jia, Zhang ZongKang, Li Jie, Lv Quanxia, He Xiaojuan, Guo Baosheng, Guan Daogang, Yu Yuanyuan, Dang Lei, Wu Xiaohao, Li Yongshu, Chen Guofen, Jiang Feng, Sun Shiguo, Zhang Bao-Ting, Lu Aiping & Zhang Ge. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. December 2017. Nature Communications 8(1)

  5. Chen Man, Yu Yuanyuan, Jiang Feng, Zhou Junwei, Li Yongshu, Liang Chao, Dang Lei, Lu Ai-Ping and Zhang Ge. Development of cell-SELEX technology and its application in cancer diagnosis and therapy. International journal of molecular sciences.

  6. 17.Li Jingjing, Yang Yongbo, Dong Yanming, Li Yongshu, Huang Yu, Yi Qianhui, Liu Kaiyu and Li Yi. (2013). Key elements of the human bocavirus type 1 (HBoV1) promoter and its trans -activation by NS1 protein. Virology Journal 10(1): 1-9.

  7. 18.Sun Bin, Cai Yingyue, Li Yongshu, Li Jingjing, Liu Kaiyu, Li Yi and Yang Yongbo. (2013). The nonstructural protein NP1 of human bocavirus 1 induces cell cycle arrest and apoptosis in Hela cells. Virology 440(1): 75-83.

  8. Sun Bin, Li Yongshu, Dong Yanming, Liu Kaiyu, Yang Yongbo and Li Yi (2013). Modulation of cellular transcriptional factors by human bocavirus 1 nonstructural protein NP1. Wei Sheng Wu Xue Bao 53(7): 737-745.

  9. 薛志超,曾嘉明,李永淑等.接种数量对细胞生长和药物作用的影响及细胞计数方法对比[J].计量学报,2023,44(03):341-349.

  10. 薛志超,赵佳威,李永淑等.细胞密度对抗癌药药效评估准确性的研究[J].计量科学与技术,2023,67(04):57-62+56


 ■专利

（1）美国专利/国际PCT：U.S. Provisional Patent Application No 63/267,737; [Aptamers Specific to EBV-Associated Malignancies and Their Applications in Cancer Imaging and Therapies] is now under application. Inventors: TSANG, Anna Chi Man, LI, Yongshu, LO, Kwok Wai; Publication Number: WO/2023/151596, Publication Date: 17.08.2023, International Application No.: PCT/CN2023/075031, International Filing Date: 08.02.2023

（2）中国专利：识别赭曲霉素A纳米抗体的核酸适配体及其筛选方法与应用；刘细霞,侯莹钰,侯建军,吴琴,刘焕,李永淑；申请号：202311182694.0发文序号：2023091400569360

（3）中国专利：一种靶向降解细胞内BCL-3 的PROTAC 化合物及其制备方法与应用; 赵静,李宾宾,李永淑,毕波,张常华,何裕隆;申请号：2023117798978发文序号：2023122201679230.

（4）中国专利：特异性识别细交链孢菌酮酸的核酸适配体及其筛选方法与应用;刘细霞,秦雁琳,刘焕,李永淑,吴琴,侯建军;申请号：2024109543115发文序号：2024071700550950.


 ■其他成果

（1）郭伟强，陈新明，江峰著，杨天逸，李永淑（副主编）。微生物中药双向发酵与养肤工程。江南出版社，2021.5. ISBN 978-988-74497-9-9.